Cost analysis for CPT A9607 — Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
Average Medicare Payment
$197.94
2023 data
Total Payments (2023)
$84.9M
Services (2023)
430.0K
Price Change (2022–2023)
-2.7%
| Year | Avg Payment | Total Payments | Services | YoY Change |
|---|---|---|---|---|
| 2022 | $203.40 | $11.9M | 60.1K | — |
| 2023 | $197.94 | $84.9M | 430.0K | -2.7% |
The most expensive state pays 1.4x more than the cheapest for this procedure. GA averages $245.29 vs NJ at $179.22.
| State | Avg Payment | Total Payments | Services | Providers |
|---|---|---|---|---|
| GA | $245.29 | $4.9M | 20.2K | 3 |
| VA | $221.48 | $5.9M | 26.8K | 3 |
| ME | $202.52 | $1.8M | 9.0K | 1 |
| AR | $198.62 | $1.3M | 6.6K | 2 |
| TX | $197.79 | $13.0M | 65.6K | 5 |
| MD | $195.85 | $9.1M | 46.6K | 1 |
| CO | $193.64 | $2.0M | 10.3K | 2 |
| NM | $193.63 | $2.0M | 10.1K | 1 |
| WA | $193.41 | $5.2M | 26.7K | 3 |
| NE | $193.28 | $3.5M | 18.1K | 2 |
| MI | $193.19 | $4.9M | 25.4K | 2 |
| LA | $192.40 | $1.5M | 7.8K | 1 |
| AZ | $192.36 | $8.6M | 44.5K | 6 |
| ID | $190.83 | $687.0K | 3.6K | 1 |
| FL | $190.59 | $13.2M | 69.1K | 7 |
| CA | $190.00 | $1.5M | 8.0K | 1 |
| PA | $187.53 | $3.8M | 20.4K | 1 |
| NJ | $179.22 | $2.0M | 11.1K | 2 |
| Provider | Specialty | State | Payments | Services | Avg/Service |
|---|---|---|---|---|---|
| Michael Morris | Diagnostic Radiology | MD | $9.1M | 46.6K | $195.85 |
| Robert Mcdonald | Nuclear Medicine | FL | $5.4M | 28.6K | $187.44 |
| Brandon Mancini | Radiation Oncology | MI | $4.5M | 23.2K | $193.14 |
| Ebrahim Delpassand | Nuclear Medicine | TX | $4.4M | 21.4K | $206.26 |
| Ashok Muthukrishnan | Nuclear Medicine | PA | $3.8M | 20.4K | $187.53 |
| Brennen Cheek | Radiation Oncology | TX | $3.6M | 18.6K | $193.91 |
| Gregory Maggass | Radiation Oncology | AZ | $3.4M | 17.9K | $192.71 |
| Stanislav Spiridonov | Diagnostic Radiology | TX | $3.1M | 15.8K | $193.39 |
| Petros Nikolinakos | Medical Oncology | GA | $2.8M | 11.5K | $243.47 |
| Victor Archie | Radiation Oncology | VA | $2.6M | 10.2K | $255.29 |
| Kevin Sanders | Radiation Oncology | WA | $2.6M | 13.4K | $193.80 |
| David Diamond | Radiation Oncology | FL | $2.5M | 13.2K | $187.05 |
| Glen Gejerman | Radiation Oncology | NJ | $2.0M | 11.0K | $179.37 |
| Gregg Franklin | Radiation Oncology | NM | $2.0M | 10.1K | $193.63 |
| Luke Nordquist | Medical Oncology | NE | $1.9M | 9.6K | $193.52 |
| Grenville Jones | Radiation Oncology | ME | $1.8M | 9.0K | $202.52 |
| Daniel Mark | Radiation Oncology | FL | $1.7M | 9.1K | $187.32 |
| Gregory Sibley | Radiation Oncology | VA | $1.7M | 8.2K | $204.23 |
| Harold Agbahiwe | Radiation Oncology | VA | $1.7M | 8.4K | $197.11 |
| Samuel Mehr | Nuclear Medicine | NE | $1.6M | 8.5K | $193.01 |
Based on the data, CPT A9607 shows a 1.4x variation in pricing across states — relatively consistent by Medicare standards.
Costs have decreased 2.7% since 2022. Medicare's fee schedule attempts to standardize pricing, though some variation is expected due to geographic cost-of-living adjustments and practice expense differences.
This analysis is based on publicly available CMS data and does not account for patient complexity, comorbidities, or facility-specific factors that may justify pricing differences.
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.